We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+29.52%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.72B
AUM Growth
+$775M
Cap. Flow
-$10.2M
Cap. Flow %
-0.22%
Top 10 Hldgs %
24.37%
Holding
169
New
21
Increased
56
Reduced
46
Closed
14

Top Buys

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$54.7M
2
EAR
Eargo, Inc. Common Stock
EAR
+$37.9M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$37.2M
4
SPRB
Spruce Biosciences
SPRB
+$36M
5
LUNG icon
Pulmonx
LUNG
+$24.5M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$135M
2
CNC icon
Centene
CNC
+$37.5M
3
BAX icon
Baxter International
BAX
+$27.2M
4
ASMB icon
Assembly Biosciences
ASMB
+$24.1M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$21M

Sector Composition

Rank Sector Weight
1 Healthcare 92.97%
2 Consumer Staples 1.52%
3 Consumer Discretionary 0.76%
4 Industrials 0.46%
5 Financials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
1
Neurocrine Biosciences
NBIX
$16.8B
$151M 3.2%
1,575,000
+109,500
+7% +$10.6M
IRTC icon
2
iRhythm Holdings
IRTC
$3.85B
$148M 3.14%
625,000
– –
UNH icon
3
UnitedHealth
UNH
$376B
$142M 3.01%
405,000
– –
HUM icon
4
Humana
HUM
$43.7B
$117M 2.48%
285,000
+42,500
+18% +$17.7M
ZLAB icon
5
Zai Lab
ZLAB
$2.06B
$116M 2.45%
854,899
+31,372
+4% +$3.19M
AGIO icon
6
Agios Pharmaceuticals
AGIO
$1.79B
$109M 2.32%
2,523,521
+942,012
+60% +$37.2M
ISRG icon
7
Intuitive Surgical
ISRG
$127B
$98.2M 2.08%
360,000
– –
BPMC
8
DELISTED
Blueprint Medicines
BPMC
$94.4M 2%
842,000
-110,773
-12% -$11.7M
ALGN icon
9
Align Technology
ALGN
$12.1B
$87.4M 1.85%
163,500
+20,500
+14% +$9.22M
ACAD icon
10
Acadia Pharmaceuticals
ACAD
$4.43B
$86.2M 1.83%
1,612,500
+39,300
+2% +$1.95M
ARGX icon
11
argenx
ARGX
$53.4B
$84.6M 1.79%
287,500
– –
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$82M 1.74%
373,152
+24,391
+7% +$5.27M
PODD icon
13
Insulet
PODD
$11.5B
$81.3M 1.72%
318,000
+2,500
+0.8% +$620K
RARE icon
14
Ultragenyx Pharmaceutical
RARE
$2.45B
$78.4M 1.66%
566,500
-10,341
-2% -$1.23M
NVTA
15
DELISTED
Invitae Corporation
NVTA
$77.4M 1.64%
1,852,067
+334,105
+22% +$16M
HCA icon
16
HCA Healthcare
HCA
$87.2B
$74M 1.57%
450,000
-50,000
-10% -$7.31M
FRPT icon
17
Freshpet
FRPT
$2.93B
$71.9M 1.52%
506,500
– –
AVIR icon
18
Atea Pharmaceuticals
AVIR
$376M
$70.9M 1.5%
+1,697,403
New +$54.7M
NVRO
19
DELISTED
NEVRO CORP.
NVRO
$68.4M 1.45%
395,000
+9,000
+2% +$1.46M
EXAS
20
DELISTED
Exact Sciences
EXAS
$64.3M 1.36%
485,000
+61,000
+14% +$7.38M
ARVN icon
21
Arvinas
ARVN
$518M
$63.4M 1.34%
746,000
+264,532
+55% +$9.12M
NVAX icon
22
Novavax
NVAX
$1.2B
$62.8M 1.33%
563,205
-22,500
-4% -$2.39M
IDXX icon
23
Idexx Laboratories
IDXX
$44.1B
$62.5M 1.32%
125,000
– –
PCRX icon
24
Pacira BioSciences
PCRX
$1.04B
$61.3M 1.3%
1,025,000
+20,000
+2% +$1.17M
ONC
25
BeOne Medicines Ltd
ONC
$32.8B
$58.1M 1.23%
225,000
+10,000
+5% +$2.75M
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return

Rock Springs Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Rock Springs Capital Management held 169 positions worth $4.72B, up 20% from $3.94B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rock Springs Capital Management's Q4 2020 filing shows 21 new, 56 increased, 46 reduced and 14 closed positions. Its largest new stake was Atea Pharmaceuticals: 1,697,403 shares worth $70.9M. The largest sale was Immunomedics Inc, an estimated $135M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 90% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q4 2020 buy was Atea Pharmaceuticals: 1,697,403 shares worth $70.9M.
  • Rock Springs Capital Management added most to Agios Pharmaceuticals in Q4 2020, an estimated $37.2M increase.
  • Rock Springs Capital Management's biggest Q4 2020 reduction was Centene, cutting an estimated $37.5M.
  • Rock Springs Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $135M.
  • Rock Springs Capital Management's ten largest holdings make up 24% of its $4.72B portfolio in Q4 2020.
  • Rock Springs Capital Management opened 21 new positions and closed 14 in Q4 2020.
  • Rock Springs Capital Management's portfolio value rose 20% quarter-over-quarter to $4.72B.

Based on Rock Springs Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.